Pangaea Oncology
Provides personalized cancer molecular diagnostics R&D and services.
Launch date
Employees
Market cap
$49.2m
Enterprise valuation
$40m (Public information from Sep 2024)
Share price
€1.47 PANG.MC
Barcelona Catalonia (HQ & founding location)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 4.1m | 4.6m | 4.4m | 8.0m | 13.8m | 14.8m | 15.7m |
| % growth | 24 % | 12 % | (5 %) | 83 % | 73 % | 7 % | 6 % |
| EBITDA | <1m | <1m | (1.2m) | (1.1m) | (1.1m) | (<1m) | <1m |
| % EBITDA margin | 17 % | 8 % | (27 %) | (13 %) | (8 %) | (2 %) | 1 % |
| Profit | (1.8m) | (<1m) | (2.7m) | (4.7m) | (1.3m) | (<1m) | (<1m) |
| % profit margin | (44 %) | (14 %) | (62 %) | (58 %) | (9 %) | (5 %) | (1 %) |
| EV / revenue | 7.9x | 7.7x | 10.4x | 7.3x | 4.4x | 4.3x | 3.9x |
| EV / EBITDA | 47.0x | 96.8x | -38.5x | -54.4x | -55.4x | -209.9x | 304.8x |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
| N/A | N/A | IPO | |
* | €12.0m | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Pangaea Oncology
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Pangaea Oncology
Edit
ACQUISITION by Pangaea Oncology Jul 2023
ACQUISITION by Pangaea Oncology Jul 2023